Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026

Capricor Therapeutics (NASDAQ: CAPR) faces a securities class action alleging FDA materials for its Dermamiocel resubmitted BLA disclosed changes to its statistical analysis plan, including that a final SAP version was reportedly not submitted or agreed with the FDA prior to the BLA submission. The article ties the alleged disclosure to a stock drop of $12.70 (-64%) to $7/share on July 27, 2026. While this is primarily litigation-related, the claims center on regulatory approval process risk and investor losses.

Analysis

This is less a new catalyst than a litigation wrapper around an already-damaged regulatory story. The near-term market mechanism is not incremental legal liability; it is that the lawsuit keeps the stock in a “broken story” state, which raises the cost of capital and makes any rescue financing, partnership, or secondary more dilutive. In a single-asset biotech, that matters more than the eventual settlement value because the equity is really pricing optionality on approval timing and label viability.

The immediate downside impulse is probably mostly exhausted, but the path over the next 1-3 months is still negative for holders because class-action headlines tend to suppress rebounds and keep the stock off institutional screens. The bigger second-order risk is that management is forced into a cash-preservation posture before the legal process resolves, which can mean slower development, weaker bargaining power with partners, and a higher probability of an ATM or PIPE into weakness. That is the real loser set: existing holders and any convertible-capital provider sitting ahead of a dilution event.

Contrarian view: the market may be over-assigning causality to the lawsuit itself when the core issue is still regulatory credibility. If the FDA process is ultimately salvageable or if the company can show that the statistical issue is immaterial, the equity can rebound sharply from depressed levels because a class action does not by itself impair operations. Falsifier for the bearish thesis is a credible FDA path forward plus no near-term financing need; absent that, any rally is likely to fade into the lead-plaintiff deadline and subsequent discovery milestones.

Key Decisions for Investors

• Do not initiate fresh long exposure in CAPR on the lawsuit alone; wait for either formal FDA clarity or a financing update, because the stock remains a binary-regulatory name with poor downside control.
• If already short-term bearish, prefer buying near-dated puts or put spreads on any relief rally rather than shorting at the lows; the post-gap borrow/borrow-cost dynamics can be unfavorable and most one-day damage is already in the price.
• Relative-value: short CAPR against XBI/IBB on strength. The thesis is not biotech-beta bearishness, but idiosyncratic dilution and process-risk drag that should underperform the basket over the next 1-3 months.
• Set an alert for any ATM, PIPE, or partnership disclosure; that is the first real tradable catalyst beyond the legal notice, and it would confirm management is forced into capital-raising mode.